UP in Blended Format for Transdiagnostic Treatment of Emotional Disorders in the Spanish National Health System
Launched by INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN · Mar 9, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating emotional disorders, such as anxiety and depression, using a method called the Unified Protocol (UP). The goal is to see how effective this blended treatment is compared to the usual care patients receive in the Spanish National Health System. The study aims to find out not just how well this new method works, but also how much it costs and how easy it is to implement.
To participate in the trial, you need to be at least 18 years old, have been diagnosed with an emotional disorder, and be fluent in Spanish. You should also have access to a smartphone and be stable on any medications you may be taking for at least three months before the study starts. Participants will receive either the new blended treatment or the standard care, and they can expect to engage in therapy that combines in-person sessions with online support. It's important to note that individuals with more severe mental health issues or who have had extensive prior therapy may not be eligible for this study. If you think this trial might be right for you or someone you know, feel free to discuss it with a healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Principal diagnosis of Emotional disorder (Evaluated by MINI interview)
- • The patient is over 18 years of age
- • The patient is fluent in the language in which the therapy is performed (Spanish in the present study)
- • To have a Smartphone
- • Patients taking pharmacological treatment for their ED will be asked to maintain the same dosages and medications for at least 3 months prior to enrolling in the study and during the whole treatment
- • The patient signs the informed consent form.
- Exclusion Criteria:
- • The patient presents a severe condition that would require to be prioritized for treatment, these include a severe mental disorder (bipolar disorder, schizophrenia, or an organic mental disorder), suicide risk at the time of assessment, or substance use in the last three months
- • The patient has previously received 8 or more sessions of psychological treatment with clear and identifiable Cognitive behavioral therapy (CBT) principles within the past 5 years.
About Instituto De Investigación Sanitaria Aragón
Instituto de Investigación Sanitaria Aragón (IIS Aragón) is a leading clinical research organization dedicated to advancing healthcare through innovative research and collaboration. Based in Spain, IIS Aragón focuses on translational medicine, bridging the gap between laboratory discoveries and clinical applications. The institute fosters a multidisciplinary approach, bringing together experts from various fields to enhance the quality and efficiency of clinical trials. With a commitment to ethical standards and patient safety, IIS Aragón plays a pivotal role in driving scientific advancements and improving health outcomes in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vinaròs, Comunidad Valenciana, Spain
Patients applied
Trial Officials
Jorge Osma, Ph.D
Principal Investigator
Instituto de Investigación Sanitaria de Aragón, Universidad de Zaragoza
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials